Ripretinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 50 mg
Reference Brands: Qinlock (USA/EU)
Category:
Oncology Cancer Care
Ripretinib is available in Tablets
and strengths such as 50 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ripretinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ripretinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ripretinib, marketed under the brand name Qinlock®, is an orally administered targeted anticancer medication approved for the treatment of adults with advanced gastrointestinal stromal tumor (GIST). GIST is a rare type of cancer that originates in the gastrointestinal tract and is commonly driven by activating mutations in the receptor tyrosine kinases KIT or platelet-derived growth factor receptor alpha (PDGFRA). Ripretinib is indicated as a fourth-line therapy for patients whose disease has progressed after prior treatment with multiple kinase inhibitors.
Ripretinib is a small-molecule inhibitor designed to broadly suppress KIT and PDGFRA signaling. Its unique dual mechanism of action enables it to inhibit a wide range of primary and secondary mutations that commonly develop after successive treatment lines, contributing to drug resistance. This broad mutation coverage makes ripretinib an important option for heavily pretreated patients.
The clinical benefit of ripretinib was demonstrated in the pivotal phase III INVICTUS trial, which showed a significant improvement in progression-free survival compared with placebo. Efficacy was observed across multiple KIT mutation subtypes, including exon 9, 11, 13, and 17. Ripretinib has an acceptable tolerability profile, with common severe adverse events including lipase elevation, hypertension, fatigue, and hypophosphataemia, supporting its role as a valuable therapy in advanced GIST management.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing